期刊文献+

广泛神经源性损害患者的临床分析

The clinical analysis of patients with generalized distribution of neurogenic involvement
原文传递
导出
摘要 目的进一步研究肌萎缩性侧索硬化(ALS)的诊断及预后。方法2008年2月~2010年1月间因缓慢起病、逐渐进展的肌肉无力、萎缩、痉挛、束颤就诊,且针肌电图呈广泛神经源性损害者均纳入登记建档;记录首发起病部位、修订肌萎缩侧索硬化功能评分(ALSFRS-R)以及病程,并分析临床特点。结果(1)广泛神经源性损害患者共80例,19例(23.75%、19/80)为下运动神经元综合征(LMNS)患者,61例(76.25%、61/80)为不同诊断级别的ALS(Awaji-shi ma标准);其中临床肯定型24例(30%、24/80),临床拟诊型22例(27.5%、22/80),临床可能型15例(18.75%、15/80)(χ2=0.067,P=0.381);(2)在不同诊断级别的ALS中,首发起病部位在延髓者,临床肯定型的例数多于拟诊型和可能型(P<0.05);(3)ALSFRS-R平均35.35±6.17,平均病程(27.7±22.2)年;与临床拟诊型和可能型患者组比较,肯定型组ALSFRS-R分值(31.00)更小,病程(1.64年)更短。结论广泛神经源性损害的患者中虽然不同诊断级别的ALS患者占大部分,但临床肯定型仅1/3;预后不良的因素为延髓起病、评分低和病程短。 Objective To analysis the diagnosis and prognosis of patients with amyotrophic lateral sclerosis(ALS).Methods The patients referred to our hospital between February 2008 and January 2010,who manifested clinically with muscle weakness/atrophy/cramps / fasciculation of slow onset and progression and showed with generalized distribution of neurogenic involvement on needle electromyography,were enrolled for registration.The onset lesion site,revised amyotrophic lateral sclerosis functional rating score (ALSFRS-R) and course of illness were documented,and the relevance of clinical data was analyzed.Results (1) There were totally 80 patients with generalized distribution of neurogenic involvement,among which 19 cases(23.75%,19/80) were diagnosed as lower motor neuron syndrome(LMNS),61(76.25%、61/80) as ALS with different levels of diagnostic certainty (Awaji-shima consensus recommendations).There were 24 cases consistent with clinical definite ALS(30%,24/80),22 clinical probable (27.5%,22/80),15 clinical possible(18.75%、15/80),respectively(χ^2=0.067,P=0.381,v.s.LMNS).(2) In ALS patient with different levels of diagnostic certainty,the number of those with bulbar onset in clinical definite subgroup was significantly more than that in clinical probable and possible subgroups(P〈0.05).(3) The average ALSFRS-R was (35.35±6.17) and the course of illness was(27.7±22.2) years in all of 80 patients.Compared with clinical probable and possible subgroups,the average score of ALSFRS-R(31.00) was smaller and the course(1.64 years) was shorter significantly in clinical definite subgroup.Conclusions ALS with different levels of diagnostic certainty accounts for the majority in the patients with generalized distribution of neurogenic involvement,but the number of clinical definite ALS was only one third;the poor prognostic indicators are bulbar onset,low ALSFRS-R and short course of illness.
出处 《卒中与神经疾病》 2010年第2期76-78,82,共4页 Stroke and Nervous Diseases
基金 湖北省自然基金重点项目(2009CDA070)
关键词 广泛神经源性损害 肌萎缩侧索硬化功能评分 诊断标准 Neurogenic involvement Amyotrophic lateral sclerosis functional rating scale Diagnostic criteria
  • 相关文献

参考文献16

  • 1Rowland LP,Shneider NA.Amyotrophic Lateral Sclerosis.N Engl J Med,2001,344(22):1688-1700.
  • 2Mitchell JD,Borasio GD.Amyotrophic lateral sclerosis.Lancet,2007,369 (9578):2031-2041.
  • 3曾艳平,肖哲曼,孙瑞迪,卢祖能.肌萎缩侧索硬化研究进展[J].卒中与神经疾病,2010,17(1):63-64. 被引量:2
  • 4Brooks BR,Miller RG,Swash M,et al.World Federation of Neurology Research Group on Motor Neuron Diseases.El Escorial revisited:revised criteria for the diagnosis of amyotrophic lateral sclerosis.Amyotroph Lateral Scler Other Motor Neuron Disord,2000,1(5):293-299.
  • 5吕传真,蒋雨平.肌萎缩侧索硬化的诊断标准(草案)[J].中华神经科杂志,2001,34(3):190-190. 被引量:100
  • 6de Carvalho M,Dengler R,Eisen A,et al.Electrodiagnostic criteria for diagnosis of ALS.Clin Neurophysiol,2008,119(3):497-503.
  • 7Kraemer M,Buerger M,Berlit P.Diagnostic problems and delay of diagnosis in amyotrophic lateral sclerosis.Clin Neurol Neurosurg,2010,112(2):103-105.
  • 8Armon C.From clues to mechanisms:understanding ALS initiation and spread.Neurology,2008,16,71(12):872-873.
  • 9Sabatelli M,Madia F,Conte A,et al.Natural history of young-adult amyotrophic lateral sclerosis.Neurology,2008,16,71(12):876-881.
  • 10Gordon PH,Cheng B,Katz IB,et al.Clinical features that distinguish PLS,upper motor neuron-dominant ALS,and typical ALS.Neurology,2009,72(22):1948-5192.

二级参考文献28

  • 1Rowland LP, Shneider NA. Amyotrophic Lateral Sclerosis. N Engl J Med, 2001, 344(22) : 1688-700.
  • 2Mitchell JD, Borasio GD. Amyotrophic lateral sclerosis. Lancet, 2007, 369(9578) :2031-41.
  • 3Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population: validation of a scoring system and a model for survival prediction. Brain, 1995, 118: 707-19.
  • 4World Federation of Neurology Research Group on Motor Neuron Diseases. Revised criteria for the diagnosis of amyotrophie lateral sclerosis. Amyotroph Lateral Se Other Motor Neuron Disord, 2000, 1 (5) : 293-300.
  • 5Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci, 2006, 7 (9) :710-23.
  • 6Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature, 1993, 362(6415):59-62.
  • 7Saeed M, Yang Y, Deng HX, et al. Age and founder effect of SOD1 A4V mutation causing ALS. Neurology, 2009, 72(19): 1634-9.
  • 8Kabashi E, Valdmanis PN, Dion P, et al. TARDP mutations in individuals with sporadic and familial amyotrophic lateral sclero sis. Nat Genet, 2008, 40(5): 572-4.
  • 9Sreedharan J, Blair IP, Tripathi VB, et al. TDP 43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science, 2008, 319(5870) : 1668-72.
  • 10Del 13o R, Ghezzi S, Corti S, et al. TARDBP (TDP43) sequence analysis in patients with familial and sporadic ALS: identification of two novel mutations. Eur J Neurol, 2009, 16 (6) : 727-32.

共引文献117

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部